University of Helsinki
Klefström lab
Oncogenic signaling pathways as therapeutic targets in breast cancer
Our laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer.
Pharmacological intervention of SARS-CoV-2 entry mechanisms by blockade of TMPRSS activity
The Klefström laboratory has been identifying and developing chemical and pharmacological inhibitors against hepsin/TMPRSS family members for a long time with the goal of preventing cancer invasion. Some of our drugs or drug-like molecules could be repurposed to prevent SARS-CoV-2 entry to cells, potentially offering a fast-track treatment option for the COVID-19 disease.
Public Outreach – Follow our team!
Klefström lab on facebook
University of Helsinki is highlighting one of Klefström lab's grad students, Rita Turpin, on their instagram page. We are happy to promote breast cancer awareness, as well as highlight our efforts to boost Finnish capabilities in cancer immunotherapy (cancerio.org). Rita will share snippets of her working day through the 'stories' feature on IG for the next 24hrs. #scicomm #breastcancerawareness
Klefström lab summer student summit 2020! Our summer students had their first opportunity to present what they have been up to. Great work, students and supervisors!
We feel privileged to have presented twice (a minisymposium and a poster session) at the annual AACR meeting. Thank you for joining us, and for the active Q and A session. We appreciate your curiosity and support.
#aacr2020
Great news! CancerIO is launching in Finland. 🥳
"The coming age of IO will have a transformative impact on fundamental and clinical cancer research, healthcare systems, business and, most importantly, on the lives of cancer patients."
Check out the whole article:
www.helsinki.fi/en/news/health-news/10-million-euros-investment-boosts-finnish-capabilities-in-ca...